These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37497166)

  • 1. Advanced Glycation End Products' Receptor DNA Methylation Associated with Immune Infiltration and Prognosis of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Yang J; Lin M; Zhang M; Wang Z; Lin H; Yu Y; Zheng Q; Chen X; Wu Y; Yao Q; Li J
    Genet Res (Camb); 2023; 2023():7129325. PubMed ID: 37497166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Zhang W; Li T; Hu B; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820957030. PubMed ID: 33084541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein phosphatase 1 regulatory subunit 3G (PPP1R3G) correlates with poor prognosis and immune infiltration in lung adenocarcinoma.
    Zhuo X; Chen L; Lai Z; Liu J; Li S; Hu A; Lin Y
    Bioengineered; 2021 Dec; 12(1):8336-8346. PubMed ID: 34592886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased expression of JAK1 associated with immune infiltration and poor prognosis in lung adenocarcinoma.
    Cai J; Deng H; Luo L; You L; Liao H; Zheng Y
    Aging (Albany NY); 2020 Dec; 13(2):2073-2088. PubMed ID: 33323549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential
    Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unveiling ficolins: diagnostic and prognostic biomarkers linked to the Tumor Microenvironment in Lung Cancer.
    Zhang Z; Geng X; Yin M; Zhang S; Liu Y; Hu D; Zheng G
    World J Surg Oncol; 2024 Oct; 22(1):273. PubMed ID: 39390580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PKM2 is a potential prognostic biomarker and related to immune infiltration in lung cancer.
    Yin L; Shi J; Zhang J; Lin X; Jiang W; Zhu Y; Song Y; Lu Y; Ma Y
    Sci Rep; 2023 Dec; 13(1):22243. PubMed ID: 38097666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential prognostic impact and potential molecular mechanisms of PCDHGA12 expression in lung adenocarcinoma and squamous cell carcinoma.
    Xu X; Zhang J; Yao T; Zhao X; Wu Q; Lu C; Guo X; Xie S; Qiu L; Bi R; Xue H
    Int Immunopharmacol; 2024 Sep; 139():112727. PubMed ID: 39067405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of
    Lin H; Wang J; Shi Q; Wu M
    PeerJ; 2024; 12():e17338. PubMed ID: 38708353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
    Xu XL; Gong Y; Zhao DP
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
    Yang K; Wu Y
    BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIAA1199 Correlates With Tumor Microenvironment and Immune Infiltration in Lung Adenocarcinoma as a Potential Prognostic Biomarker.
    Shen X; Mo X; Tan W; Mo X; Li L; Yu F; He J; Deng Z; Xing S; Chen Z; Yang J
    Pathol Oncol Res; 2022; 28():1610754. PubMed ID: 36419650
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic value of immune-related genes in the tumor microenvironment of lung adenocarcinoma and lung squamous cell carcinoma.
    Qu Y; Cheng B; Shao N; Jia Y; Song Q; Tan B; Wang J
    Aging (Albany NY); 2020 Mar; 12(6):4757-4777. PubMed ID: 32209727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant Expression of β-Catenin Correlates with Infiltrating Immune Cells and Prognosis in NSCLC.
    Zheng H; Ning Y; Yang Y; Zhan Y; Wang H; Wen Q; Peng J; Fan S
    Pathol Oncol Res; 2021; 27():1609981. PubMed ID: 34764821
    [No Abstract]   [Full Text] [Related]  

  • 16.
    Yi C; Zang N; Gao L; Ren F
    Aging (Albany NY); 2024 May; 16(11):9498-9517. PubMed ID: 38819947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysophosphatidic Acid Receptor 6 (LPAR6) Is a Potential Biomarker Associated with Lung Adenocarcinoma.
    He J; Gao R; Meng M; Yu M; Liu C; Li J; Song Y; Wang H
    Int J Environ Res Public Health; 2021 Oct; 18(21):. PubMed ID: 34769557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
    Hou G; Lu Z; Bi Y; Deng J; Yang X
    Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
    Tian WJ; Liu SS; Li BR
    Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
    Yang Y; Wang M; Liu B
    J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.